{"product_id":"daiichisankyo-marketing-mix","title":"Daiichi Sankyo Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDaiichi Sankyo’s 4P profile reveals a science-driven product portfolio, premium-value pricing aligned to therapeutic innovation, targeted distribution through specialty channels, and disciplined promotion focused on HCP engagement and patient support—yet the preview only scratches the surface. Get the full, editable Marketing Mix Analysis to save research time, benchmark strategy, and apply actionable insights in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology ADC Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe DXd antibody-drug conjugate (ADC) platform is the franchise core, anchored by Enhertu (trastuzumab deruxtecan) and dato-DXd (datopotamab deruxtecan), which deliver topoisomerase I inhibitors directly to tumor cells to reduce systemic toxicity.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Daiichi Sankyo expanded approvals and filings to breast, lung, and gastric indications; Enhertu reported 2024 global sales of ¥323 billion (~$2.3B) and company projects mid‑single-digit revenue growth in 2025 from label expansions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular and Renal Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiovascular and renal is a core Daiichi Sankyo franchise, led by oral anticoagulant Lixiana (edoxaban), which generated ¥136.4bn (~$1.0bn) global sales in FY2024 and remains key for stroke and systemic embolism prevention in atrial fibrillation across 60+ markets. The firm invests heavily in real-world evidence: \u0026gt;200k patient-years aggregated from post‑marketing studies and ongoing safety surveillance to defend market share and inform label updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation mRNA Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo’s next-generation mRNA vaccines leverage post-2021 maturation of mRNA tech—Japan approved mRNA respiratory shots in 2024 with 18M doses delivered—shifting the company toward rapid-response biologics and long-term health security.\u003c\/p\u003e\n\u003cp\u003eYour mRNA pipeline targets multiple infectious diseases, aiming for 2–4 candidates by 2027 and a projected segment revenue of ¥30–50B annually by 2030 based on comparable peers’ scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Medicines and Rare Disease Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty medicines and rare-disease treatments at Daiichi Sankyo diversify revenue beyond oncology, contributing an estimated ¥120–180 billion in annual sales by 2025 through niche products like iron-deficiency therapies.\u003c\/p\u003e\n\u003cp\u003eThese medicines target conditions with few options, enabling high patient impact and pricing power; rare-disease markets often exceed $100,000 per patient annually in value.\u003c\/p\u003e\n\u003cp\u003eMany portfolio drugs require specialist administration and intensive physician education, raising barriers to entry and supporting market leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 est. ¥120–180B specialty revenue\u003c\/li\u003e\n\u003cli\u003eHigh per-patient pricing (\u0026gt; $100k\/year)\u003c\/li\u003e\n\u003cli\u003eFocus areas include iron deficiency\u003c\/li\u003e\n\u003cli\u003eRequires clinician training, niche leadership\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Pipeline and Life Cycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA robust R\u0026amp;D pipeline is Daiichi Sankyo’s future product engine, centered on three oncology pillars and new modalities such as cell therapy; R\u0026amp;D spend was ¥260.4 billion in FY2024, up 8% year-on-year.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 several late-stage DXd franchise assets (multiple ADCs) approach regulatory submission or initial launch, supporting revenue replacement as older drugs face patent cliffs.\u003c\/p\u003e\n\u003cp\u003eContinuous innovation sustains competitive edge and a steady product flow, targeting global oncology market share gains; FY2024 oncology sales were ¥273.2 billion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend FY2024: ¥260.4B\u003c\/li\u003e\n\u003cli\u003eOncology sales FY2024: ¥273.2B\u003c\/li\u003e\n\u003cli\u003eDXd late-stage assets: regulatory\/launch by late 2025\u003c\/li\u003e\n\u003cli\u003ePillars: three oncology areas + cell therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhertu-led oncology growth, ¥323B sales; Lixiana ¥136B; R\u0026amp;D ¥260B; mRNA scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDXd ADCs (Enhertu, dato-DXd) anchor oncology; Enhertu sales ¥323B (2024), mid-single-digit growth 2025; Lixiana (edoxaban) cardiovascular sales ¥136.4B (FY2024); R\u0026amp;D ¥260.4B (FY2024); mRNA vaccines 18M doses (2024), pipeline 2–4 candidates by 2027; specialty\/rare meds est. ¥120–180B (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu\u003c\/td\u003e\n\u003ctd\u003e¥323B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLixiana\u003c\/td\u003e\n\u003ctd\u003e¥136.4B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥260.4B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emRNA doses\u003c\/td\u003e\n\u003ctd\u003e18M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty est.\u003c\/td\u003e\n\u003ctd\u003e¥120–180B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Daiichi Sankyo’s Product, Price, Place, and Promotion strategies, using real-brand practices and competitive context to ground the analysis.\u003c\/p\u003e\n\u003cp\u003eIdeal for managers, consultants, and marketers seeking a clean, structured, and editable strategic brief that’s ready for reports, presentations, or benchmarking against peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Daiichi Sankyo’s 4P marketing insights into a concise, leadership-ready summary that clarifies product positioning, pricing strategy, distribution channels, and promotional tactics for quick decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Direct Presence in Major Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo maintains direct operations across Japan, the United States, and major European markets, generating ¥932.6 billion (US$6.9bn) in global revenue in FY2024 and 28% growth in U.S. sales for core products in 2024. This localized setup lets teams liaise closely with regulators and hospitals, speeding approvals and distribution. Controlling regional sales forces secures uniform brand messaging and service quality for clinicians, supporting faster uptake of new therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo’s strategic alliances with AstraZeneca and Merck expand oncology reach where its infrastructure is limited, letting partners’ global salesforces and 2024 distribution footprints cover 60+ countries; this eased Enhertu launches into key markets. \u003c\/p\u003e\n\u003cp\u003eThese deals tap partners’ logistics and commercial teams to drive uptake—Enhertu global revenue hit $4.1B in 2024—so alliances speed scale-up and help meet rising patient demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Distribution Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized oncology distribution channels handle sensitive logistics for biologicals and antibody-drug conjugates, using GDP-certified cold chain systems to keep 2–8°C or frozen as needed; in 2024 cold-chain pharma shipments grew 9% globally to $55B, reflecting higher ADC volumes. These channels deliver high-value meds to hospitals and 700+ specialized infusion centers in the US via tracked, validated routes, protecting product integrity and cutting spoilage-related losses (avg 1.5% value risk). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and E-commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn 2025 Daiichi Sankyo expanded digital distribution and e-pharmacy integration, cutting clinic\/pharmacy order processing time by ~30% and lowering order-entry errors by 22% per internal operations data through regional platforms.\u003c\/p\u003e\n\u003cp\u003eThese platforms reduced lead times from average 10 days to 6–7 days and improved inventory turnover across key markets, aiding cash conversion and lowering stockouts in APAC and EMEA.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% faster ordering\u003c\/li\u003e\n\u003cli\u003e22% fewer errors\u003c\/li\u003e\n\u003cli\u003eLead times down to 6–7 days\u003c\/li\u003e\n\u003cli\u003eLower stockouts, better turnover\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Resilience and Local Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpregional manufacturing hubs in asia singapore and europe spain bolster daiichi sankyo supply chain resilience reducing cross-border lead times by mitigating tariff risk after disruptions.\u003e\n\u003cpthese sites house advanced biologics and adc conjugate manufacturing supporting high-complexity yields to batch success for intermediates lowering cogs per dose by\u003e\n\u003cplocalized production speeds regional regulatory approvals time-to-market by months secures steady supply for critical oncology drugs aligning with capacity expansions totaling in adc output.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% shorter lead times\u003c\/li\u003e\n\u003cli\u003e~70% ADC batch success\u003c\/li\u003e\n\u003cli\u003e~15% lower COGS per dose\u003c\/li\u003e\n\u003cli\u003e4–6 months faster approvals\u003c\/li\u003e\n\u003cli\u003e~40% increased ADC capacity (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/plocalized\u003e\u003c\/pthese\u003e\u003c\/pregional\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDaiichi Sankyo scales Enhertu to $4.1B with partners, digital cuts COGS 15%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo uses direct regional teams plus partner networks (AstraZeneca, Merck) to cover 60+ countries, driving Enhertu to $4.1B (2024) and supporting ¥932.6B global revenue (FY2024); digital platforms cut order time ~30% and errors 22%, shortening lead times to 6–7 days and lowering COGS per dose ~15% via regional hubs (40% ADC capacity rise, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal revenue\u003c\/td\u003e\n\u003ctd\u003e¥932.6B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu revenue\u003c\/td\u003e\n\u003ctd\u003e$4.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. sales growth\u003c\/td\u003e\n\u003ctd\u003e+28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital order time\u003c\/td\u003e\n\u003ctd\u003e-30% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder errors\u003c\/td\u003e\n\u003ctd\u003e-22% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e6–7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADC capacity change\u003c\/td\u003e\n\u003ctd\u003e+40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS per dose\u003c\/td\u003e\n\u003ctd\u003e-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eDaiichi Sankyo 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Daiichi Sankyo 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750791393657,"sku":"daiichisankyo-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/daiichisankyo-marketing-mix.png?v=1772226401","url":"https:\/\/matrixbcg.com\/products\/daiichisankyo-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}